086060 — Genebiotech Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMicro CapValue Trap

Annual income statement for Genebiotech Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	59,119	62,814	82,759	79,477	82,959
Cost of Revenue
Gross Profit	9,572	7,577	10,498	13,793	13,507
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	57,354	63,178	81,118	76,114	79,116
Operating Profit	1,765	-365	1,640	3,363	3,844
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-420	-838	1,815	3,374	3,503
Provision for Income Taxes
Net Income After Taxes	-61.5	-484	1,523	2,591	2,865
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-2,341	-484	1,523	2,591	2,865
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-2,341	-484	1,523	2,591	2,865
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-16.2	-44	180	352	321
Dividends per Share